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Abstract
 .We have recently demonstrated that the phospholipid platelet-activating factor PAF mediates an autocrine proliferative
loop in the endometrial adenocarcinoma cell line HEC-1A. In the present study we investigated the signaling pathways
involved in PAF-mediated increase of proliferation in these cells. In particular, we studied the effect of PAF on protein
 .tyrosine phosphorylation and mitogen-activated protein kinase MAPK activity, as well as the effect of protein tyrosine
 .  .kinase PTK and protein kinase C PKC inhibition on PAF-induced increase of c-fos gene expression and thymidine
incorporation in HEC-1A cells. We found that PAF induced a rapid, time- and dose-dependent increase of tyrosine
phosphorylation of a subset of proteins of 42, 44, 78, 99, and 150 kDa molecular weight. We also found that PAF increased
tyrosine phosphorylation and activity of p42 MAPK, suggesting the involvement of this important intermediary enzyme in
the proliferative effect of PAF. The effect of PAF on c-fos gene expression was not prevented by pre incubation with the
PTK inhibitors genistein or methyl-2,5-dihydroxycinnamate, whereas was strongly affected by PKC down regulation after
long term incubation with PMA or by PKC inhibition with sangivamycin. We also found that genistein and methyl
w3 x2,5-dihydroxycinnamate decreased both basal and PAF-stimulated H thymidine uptake in these cells. Similar results were
w3 xobtained with PD 098059, a specific inhibitor of MAP kinase cascade. PAF-stimulated H thymidine uptake was also
prevented by PKC down regulation after long term exposure to PMA and PKC inhibition with the two inhibitors
sangivamycin and bis-indolylmaleimide. In conclusion, our results indicate that PAF-induced mitogenesis in HEC-1A cells
is mediated by the activation of multiple signaling pathways, involving PTK, MAPK, and PKC activation.
Keywords: Platelet-activating factor; HEC-1A; Endometrial adenocarcinoma; Protein kinase C; Protein tyrosine kinase; Mitogen-activated
protein kinase
1. Introduction
Tyrosine phosphorylation of proteins is considered
an essential signal in the modulation of cell prolifera-
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w xtion 1,2 . Indeed, peptide growth factors induce mi-
togenesis by stimulating a series of signaling path-
ways involving intrinsic receptor protein tyrosine ki-
 .nase PTK activation which in turn generates a
cascade of events culminating in phosphorylation in
tyrosine residues of several cell enzymes. In recent
years, evidence is emerging that PTK activation also
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occurs following stimulation with agonists whose
response is mediated by G-protein-coupled receptors
which stimulate phosphoinositides hydrolysis, mobi-
lization of Ca2q and activation of protein kinase C
w x3–9 . However, the biological function of these
 .non-receptor protein tyrosine kinases NRPTK in
proliferating and non-proliferating cells is still largely
unclear. So far, a clear linkage between NRPTK and
stimulation of proliferation has been demonstrated
w xonly for few agents 5–8 , while evidence of such a
relationship is lacking for other agonists, and the
relative importance of PKC-mediated versus
NRPTK-mediated pathways in the induction of pro-
liferation is unclear. We have recently demonstrated
an unusual mitogenic effect of platelet-activating fac-
 .tor PAF in the endometrial adenocarcinoma cell
w xline HEC-1A 10,11 . In particular, the mitogenic
effect of PAF appears to be crucial for these cells,
since the PAF antagonist L659,989 dramatically
w xblunted cell growth 11 . HEC-1A cells produce large
amounts of this phospholipid, which stimulates c-fos
gene expression, intracellular calcium increase and
thymidine uptake by interaction with specific PAF
w xreceptors 10,11 . These receptors, that have recently
w xbeen cloned 12,13 , belong to the family of seven
transmembrane domain-G protein coupled receptors.
Nonetheless, PAF has been demonstrated to stimulate
tyrosine phosphorylation of proteins both in highly
w xdifferentiated, non-proliferating cells 14–16 , and in
w xproliferating cancer cells 17–20 . Moreover, recent
data indicate that PAF can stimulate the activity of
the serinerthreonine mitogen-activated protein ki-
 . mapk mapknases MAPK p44 and p42 , also named
extracellular signal-regulated kinases ERK1 and
. w xERK2 20–22 , that are considered important inter-
mediary enzymes in converting extracellular signals
w xinto intracellular responses 23,24 , and are activated
by most mitogens. However, while the biological
function of such PAF-mediated signaling pathway in
w xnon-proliferating cells is emerging 14–16 its possi-
ble involvement in mitogenesis in proliferating cells
has not been established, and the functional conse-
quence of non-receptor protein tyrosine kinase
 .NRPTK activation by PAF in these cells is still
unknown. Therefore, HEC-1A cells represent an in-
teresting model to study a possible linkage between
NRPTK activation and induction of mitogenesis by
PAF.
We designed and performed experiments aimed to
 .investigate: i the effect of PAF on tyrosine phos-
 .phorylation of proteins in HEC-1A cells; ii the
 .effect of PAF on the activity of MAP kinase; iii the
effect of PTK and MAPK cascade inhibitors on
 .PAF-stimulated thymidine incorporation; iv in addi-
tion, to study the possible contribution of PKC-medi-
ated pathways in the mitogenic effect of PAF, we
evaluated the effect of PKC inhibition on PAF-medi-
ated thymidine uptake and c-fos gene expression.
2. Materials and methods
2.1. Chemicals
 .Sodium orthovanadate Na VO , fatty acid free3 4
 .bovine serum albumin BSA , gelatine, glycine,
trizma base, Temed, APS, Triton X-100, phenyl-
 .methylsulfonylfluoride PMSF , soybean trypsin in-
hibitor, o-phospho-DL-tyrosine, Ponceau S and Com-
massie R250, EGTA, EDTA, bovine insulin, myelin
 .basic protein MBP , McCoy’s 5A medium, fetal calf
serum, penicillin, propidium iodide and streptomycin
 .were from SIGMA St. Louis, MO . Erbstatin analog
 .methyl 2,5-dihydroxycinnamate , genistein, daidzein,
bisindolylmaleimide-HCl, platelet-activating factor
 .PAF and monoclonal anti-p42MAP kinase antibody
 .were from Calbiochem La Jolla, CA . Sangivamycin
was from National Institutes of Health Drug Synthe-
 .sis and Chemistry Branch Bethesda, MD . Unconju-
 .gated and peroxidase-conjugated monoclonal PY20
anti-phosphotyrosine antibodies were from ICN
 .Costa Mesa, CA . Reagents for sodium dodecyl
 .sulfate SDS -polyacrylamide gel electrophoresis
 .  .PAGE were from BIO-RAD Labs Hercules, CA .
Protein molecular weight standards and Tween 20
 .were from FLUKA Chemie AG Bucks, Switzerland .
 .Enhanced Chemiluminescence ECL Western blot-
ting detection reagents were from Amersham
 . w 3 x Buckinghamshire, UK . methyl- H thymidine 2
.Cirmmol was obtained from New England Nuclear
 . w 32 x w 32 xBoston, MA . g P ATP and a P ATP were from
 .  .Amersham Buckinghamshire, UK . bPc-fos human 1
cDNA probe was obtained from ATTC Rockville,
.MD . Organic solvents were purchased from Carlo
 .Erba Milan, Italy . Polyclonal anti-MAP kinase anti-
bodies a IIcp42 and a Icp44 were a generous gift
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from Dr. M.J. Dunn Medical College of Wisconsin,
. w  X XMilwaukee, WI . PD 098059 2- 2 -amino-3 -metho-
. xxyphenyl -oxanaphthalen-4-one was a generous gift
 .of Dr. A. Saltiel Parke-Davis, Ann Arbor, MI, USA .
2.2. Cells
 .HEC-1A obtained from ATCC, Bethesda, MD is
a cell line established in 1968 from explants of
endometrial adenocarcinoma. The cells were grown
 .in modified McCoy’s 5A Sigma supplemented with
10% of fetal calf serum Gibco, Grand Island, NY,
.  . USA , penicillin 10 Urml , streptomycin 0.1
.mgrml and 2.2 grl sodium bicarbonate as sug-
gested by ATCC. Cell cultures were maintained in
humidified atmosphere of 5% CO and 95% air at2
378C. Medium was replaced every 2–3 days and the
 .cells were split every 4–5 days using trypsin 0.05%
in Mg2q- and Ca2q-free PBS containing 0.02%
EDTA.
2.3. SDS-PAGE and Western blot analysis
After the different treatments, the cells were pro-
cessed for SDS-electrophoresis as previously de-
w x  .scribed 16 . Briefly, cells in 6-well plates were
stimulated as indicated and the medium quickly re-
moved. The cells were washed and scraped in PBS
containing 1 mM Na VO , then centrifuged at 400=3 4
g at 48C for 10 min and resuspended in 20 ml lysis
buffer 20 mM Tris, pH 7.4, 150 mM NaCl, 0.25%
.NP-40, 1 mM Na VO , 1 mM PMSF . After mea-3 4
surement of proteins, the cell extracts were diluted in
2= concentrated Laemmli sample buffer 62.5 mM
Tris, pH 6.8, containing 10% glycerol, 20% SDS,
.2.5% pyronin and 200 mM dithiothreitol , vortexed,
incubated at 908C for 5 min and then loaded onto
7.5% or 10% polyacrylamide-bisacrylamide gels as
indicated. After SDS-PAGE, proteins were trans-
 .ferred to nitrocellulose Sigma, St. Louis, MO ,
stained with Ponceau to verify equal loading and
immunostained with peroxidase conjugated mono-
 .clonal anti-phosphotyrosine antibody PY20 . The
phosphotyrosine antibody-reacted proteins were re-
vealed by enhanced-chemiluminescence system ECL,
.Amersham . Immunoabsorption was obtained by re-
acting the antibody with 40 mM of o-phospho-DL-
tyrosine for 1 h at room temperature. Quantification
of the bands was made directly on the films by image
analysis with a C3077r01 video camera, connected
with the video frame grabber M4477 Hamamatsu
. w xPhotonics, Japan 16 . This video frame grabber is a
plug-in board used in a Macintosh Ilsi PC Apple,
.USA . Acquisition of image was taken by Image
quest IQ Base software Hamamatsu Photonics,
.Japan . Image processing and analysis was obtained
by IMAGE free software, kindly provided by Wayne
 .Rasband NIMH, Bethesda, MD . For technical rea-
sons, quantifications were performed in ECL low-ex-
posed films.
2.4. Immunoprecipitation of MAP-kinase and MAP-
kinase acti˝ity
Cells grown on 6-well plates, washed and resus-
pended in serum-free medium, were stimulated with
PAF for the indicated times, then scraped in 1 ml
lysis buffer 20 mM Tris-HCl, 150 mM NaCl, 0.25%
.NP-40, 1 mM Na VO , 1 mM PMSF and cen-3 4
 .trifuged 12 000 rpm at 48C for 10 min . The super-
 .natants 200 mg of proteins for each sample were
incubated with 3 ml of the indicated anti-MAPK
antibody for 1 h in ice followed by incubation with
 .20 ml of Protein A-Sepharose Sigma for 2 h at 48C.
The immunocomplexes were washed 3 times with 20
mM Tris buffer, resuspended in Laemmli sample
buffer, boiled for 5 min and run on 10% SDS-PAGE.
Proteins were transferred onto nitrocellulose and
MAP-kinase was revealed with polyclonal anti-
 . w xMAPK antibody a IIcp42 25 followed by a perox-
idase-conjugated secondary antibody visualized by
ECL.
For the MAP-kinase assay the immunoprecipitates
obtained as described above, were assayed for the
ability to phosphorylate a MAPK specific substrate,
 .myelin basic protein MBP . Briefly, the extracts
were incubated with 30 ml of kinase buffer 10 mM
Hepes, pH 7.4, 20 mM MgCl 1 mM DTT, 1 mM2
Na VO , 25 mM ATP, 0.5 mgrml MBP, 250 mCi3 4
w 32 x .g P ATP for 30 min at 308C. Aliquots of 20 ml
were spotted onto phospho-cellulose, washed four
times with 1% phosphoric acid and finally with 100%
ethanol. The filters were dried and bounded radioac-
tivity determined by liquid scintillation counting.
MAPK activity was also evaluated by in gel kinase
assay, which determines the ability of kinases present
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in total cell lysates to phosphorylate MBP 0.5
.mgrml copolymerized in SDS-polyacrylamide gels
w x26,27 . After the indicated treatments, cells were
lysed and sonicated as for immunokinase. After cen-
trifugation, aliquots of the supernatants containing 10
mg of proteins were boiled in 2=Laemmli’s sample
buffer, separated on a 10% SDS-polyacrylamide gel
containing 0.5 mgrml MBP. SDS was removed from
gel by washing with two changes of 20% 2-propanol
in buffer A 50 mM Hepes, pH 7.4, 5 mM 2-
.b mercaptoethanol for 1 h at room temperature. The
gel was subsequently denaturated with 6 M guanidine
HCl in buffer A for 1 h, and then renaturated in
buffer A containing 0.04% Tween 20 for 16 h at 48C.
After 1 h preincubation in buffer B 25 mM Hepes,
pH 7.4, 10 mM MgCl2, 100 mM Na3VO4, 5 mM
.2-b mercaptoethanol, 0.5 mM EGTA , the kinase as-
say was carried out by incubating the gel at 258C for
2 h in 5 ml buffer B containing 40 mM ATP and 50
w 32 xmCi of g- P ATP. The gel was then extensively
washed with 5% trichloroacetic acid containing 1%
sodium pyrophosphate, dried under vacuum and sub-
jected to autoradiography. Quantification of the bands
was performed as described above.
2.5. Northern blot analysis of mRNA
For Northern analysis of c-fos mRNA expression,
cells were treated with PAF in the presence of the
indicated PTK or PKC antagonists for 30 min. Total
cellular RNA was prepared by the hot-phenol method
and quantificated by spectrofluorimetric analysis at
260 nm. 20 mg of RNA were fractionated in a 1%
agarose-3% formaldehyde gel, transferred onto nylon
 .membrane Nytran, Schleicher and Schuell and baked
w xat 808C for 2 h 11 . The membranes were pre-hy-
bridized for 1 h and then hybridized overnight at
 .658C with Church and Gilbert solution pH 8 con-
taining 10 mgrml BSA, 7% sodium dodecyl sulfate
 .SDS , 0.25 M sodium phosphate buffer, 1 mM
EDTA and 0.2 mgrml hot-denatured sonicated her-
ring sperm DNA. The probe used for RNA hybridiza-
 .tion was bPc-fos human 1 cDNA. To correct possible
differences in RNA loading, the same nylon mem-
branes were concomitantly or subsequently hy-
 .bridized to rat cyclophyllin coding region cDNA
probe. The probes were labelled with deoxycytidine
X w 32 x5 - a P triphosphate by a random priming kit
 .Boheringer Mannheim Italy, Milan, Italy , chro-
matographed Nu-Clean D25 Disposable Spun
.Columns, IBI, New Haven, CT, USA and hot-dena-
tured before use. The membrane was washed four
times with a solution containing 1% SDS, 0.2 M
 .Church and Gilbert buffer and 0.1 mM EDTA pH 8
at 658C for 10 min. The nylon membrane was then
submitted to autoradiography using Kodak X-Omat
AR film and Kodak X-Omatic regular intensifying
screens at y80C. Quantification of the bands was
performed as described above.
([3 ]2.6. Mitogenic assay H thymidine incorporation
)and cell counting by cytofluorimeter
w3 xH thymidine incorporation was assessed as de-
w xscribed previously 11 . Briefly, HEC-1A cells were
plated into 24-well dishes, grown until 80% conflu-
ence in complete medium, maintained for 24 h in
serum-free medium and the indicated concentrations
 .of stimuli or vehicles 10 ml added in triplicate for
24 h. Cells were then pulsed with 1 mCirwell of
w3 xH thymidine for 4 h, washed twice with ice-cold
5% TCA and solubilized with 0.25 N NaOH in SDS
 .0.1% at 37 C for 20 min. Aliquots were transferred
to plastic vials and counted by liquid scintillation.
For flow cytometry analysis, cells were incubated
 .or not with PAF 1 mM for the indicated times,
 .washed twice with cold phosphate buffer saline PBS
without calcium and magnesium and 1 ml of fluo-
 w xrochrome solution Propidium Iodine PI 0.05
mgrml, dissolved in 0.1% sodium citrate and 0.1%
.Triton X-100 added. Dishes were kept for 60–90
min in the dark at 48C, then cells were dislodged by
gentle scraping and repeated pipetting and transferred
in test tubes for cytofluorimetric analysis. Complete
removal of cells from substrate was checked by phase
contrast microscopy. Cell counting was performed by
FACScan flow cytometer Becton Dickinson, Moun-
.tain View, CA analysis. We used a suspension of
fluorescent beads as volume standard to determinate
the absolute cell number. The concentration of the
beads in the standard suspension was ascertained by a
hemocytometer and resulted 755 beadsrml. 20 ml of
the fluorescent particles suspension were added to
each sample before flow cytometer analysis. The
machine was set to count a constant number of
events. The green fluorescence of the beads was
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detected in the 515–555 nm wavelength band and
DNA fluorescence due to PI staining in the 563–607
nm wavelength band on linear scale. Cells with a
normal DNA content were considered as viable.
Number of either beads or viable cells was calculated
with the computer HP 9000 model 340, Palo Alto,
.CA interfaced to the flow cytometer. The standard
beads were gated out from linear DNA histograms.
The cell number in the test tube was calculated by
multiplication of the counted number of nuclei by the
ratio of the added to counted number of the standard
beads. Results are expressed as number of viable
cellsrdish.
2.7. Statistical analysis
Data are expressed as mean"S.E.M. Statistical
comparisons were performed by paired Student’s t-
test.
3. Results
3.1. Effect of PAF on protein tyrosine phosphoryla-
tion and MAPK acti˝ation in HEC-1A cells
Time-course of PAF-induced tyrosine phosphory-
lation of proteins in HEC-1A cells is shown in Fig.
1A. The effect of PAF was present after 30 s incuba-
tion, reached a maximum at 2 min and slightly
 .declined after 5 min Fig. 1A . PAF induced an
increase of tyrosine phosphorylation in several pro-
tein bands. Among these, bands in the molecular
weight ranges of 42, 44, 78, 99, and 150 kDa were
 .dose-dependently modulated by PAF Fig. 1B . The
specificity of the immunoreactions with the anti-
phosphotyrosine antibody to phosphotyrosine residues
was verified by previous immunoabsorption of the
w xantibody with o-phospho-DL-tyrosine 16 , which
completely abolished the immunoreactivity in the
 .different protein bands not shown . The prominent
effect of PAF on tyrosine phosphorylation of a 42-
kDa, as well as, albeit smaller, on a 44-kDa protein
 .band Fig. 1B prompted us to investigate the possi-
ble immunological identity of such bands with mito-
 .gen-activated protein kinases MAPK , by using
monoclonal and polyclonal antibodies against these
proteins. We first studied the effect of PAF on tyro-
Fig. 1. Panel A: Time-course of PAF-induced increase of tyrosine
phosphorylation in HEC-1A cells. Cells were incubated with 0.1
mM PAF for the indicated times. Cell lysates were run onto 7.5%
polyacrylamide-bisacrylamide gels followed by transfer to nitro-
cellulose. Tyrosine phosphorylated proteins were revealed using
the monoclonal antibody PY20-HRP followed by the ECL detec-
 3.tion system. Molecular weight markers =10 are indicated to
the right of the blot. Representative of two similar experiments.
Panel B: Cumulative results of at least three different experi-
ments showing the concentration-dependence of PAF 5-min
.stimulation -induced increase of tyrosine phosphorylation in the
different protein bands in HEC-1A cells. To obtain two separate
bands at 44 and 42 kDa, cell proteins were run onto 10%
polyacrylamide-bisacrylamide gels. Quantification of the bands
was performed as described in Section 2.
sine phosphorylation of MAPK by immunoprecipita-
tionranti-phosphotyrosine Western blot analysis. In
these experiments, the polyclonal antibody a IIcp42
was used to immunoprecipitate MAP kinase. Such
antibody has been shown to recognize both 42 and 44
w xkDa isoforms of MAPK 25 . As shown in Fig. 2A,
PAF induced a sustained increase of tyrosine phos-
phorylation in a protein band of approx. 42–45 kDa,
which was already evident at early time points. Such
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 .  .Fig. 2. Time-course Panel A and dose-dependence Panel B of
PAF-induced increase of tyrosine phosphorylation of MAPK in
HEC-1A cells. After stimulation with PAF, cell proteins were
immunoprecipitated with a IIcp42 antibody. After SDS-PAGE
onto 10% polyacrylamide-bisacrylamide gel, and transfer to ni-
tro-cellulose, tyrosine phosphorylated proteins were revealed us-
ing the monoclonal antibody PY20-HRP followed by the ECL
 .detection system. The arrows indicate p42 panel A and p42 and
 .p44 panel B protein bands. Representative of two similar
 .experiments. Panel C Effect of increasing concentrations of
PAF on MAPK kinase activity, evaluated by immunokinase assay
w32 xin the presence of the MAPK substrate MBP and P g-ATP.
Quantification of phosphorylated MBP was made by liquid scin-
tillation. Results are mean of duplicate of a representative out of
three similar experiments.
 .increase was dose-dependent Fig. 2B with a maxi-
mal activation at 0.1 mM concentration. In the latter
experiments, PAF-mediated increase of tyrosine
phosphorylation was evident in two protein bands
 .respectively of 42 and 44 kDa Fig. 2B , indicating
an effect of the phospholipid on both MAPK iso-
forms. We next evaluated MAP kinase activity in
PAF-stimulated HEC-1A cells by immunokinase as-
w 32 xsay in the presence of MBP and g P -ATP. When
the p42 isoform of MAPK was immunoprecipitated
by a monoclonal antibody anti-MAPK ERK2, Cal-
.biochem , we found that PAF dose-dependently stim-
ulated a three to four fold increase of MAPK activity
 .with a maximum at 0.1 M concentration Fig. 2C .
When MAPK was immunoprecipitated with the poly-
clonal a IIcp42 antibody, similar results were ob-
 .tained data not shown .
MAPK activity was also evaluated by measuring
MBP kinase activity of HEC-1A cell proteins in
polyacrylamide gels copolimerized with MBP. As
shown in Fig. 3A, at least three proteins with the
ability to phosphorylate MBP were demonstrated in
HEC-1A cells. Among these proteins, PAF treatment
 .5 min incubation caused an increase of MBP kinase
activity of a 42–44 indicated in the figure by an
.  .arrow and a 80–100 kDa proteins Fig. 3A . Such
increase was inhibited by the tyrosine kinase in-
 .  .hibitors genistein Fig. 3A and erbstatin not shown ,
and by the MAPK cascade inhibitor PD098059 Fig.
.3A , which has been indicated as a specific inhibitor
 . w xof MAPK kinase MEK activity 28–30 . The in-
hibitory effect of PD098059 was already maximum at
 .the concentration of 1 mM Fig. 3B . However, in
our hands, the compound also inhibited basal as well
 .as stimulated activity of other bands Fig. 3A irre-
 .spectively of the concentration used not shown .
3.2. Effect of tyrosine kinase inhibition on basal and
PAF-stimulated c-fos gene expression
In a previous report, we showed that mRNA ex-
pression for the early oncogene c-fos in HEC-1A
w xcells was enhanced by treatment with PAF 11 . In
order to define the role of tyrosine kinase activation
on PAF-stimulated c-fos gene expression, we utilized
w xthe two tyrosine kinase inhibitors genistein 31 and
the erbstatin analog methyl-2,5-dihydroxycinnamate
w x32 as pharmacological tools. Results of these exper-
iments are repoted in Figs. 4 and 5. The upper panels
report the hybridizing bands using a cDNA probe for
 .c-fos upper blot and for the housekeeping gene
 .cyclophyllin lower blot . In the lower panels the
percentage increase of c-fos expression with the dif-
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ferent treatments compared to control is reported.
These values represent percentage increase of the
ratios between the optical densities of c-fos and
cyclophillin mRNA bands. Pre-treatment of the cells
with 10 and 30 mM concentrations of genistein 30
.min pre incubation did not affect basal nor inhibited
 . PAF 0.1 mM -stimulated c-fos gene expression Fig.
.4 . This result was consistently obtained in at least
two different experiments and was confirmed also
 .Fig. 3. Panel A: effect of PAF 5 min incubation in the presence
 .  .or absence of genistein G or PD 098059 PD on MBP-phos-
 .phorylating activity of HEC-1A cells. Cell lysates 10 mgrlane
were resolved on a 10% SDS polyacrylamide gel containing
 .MBP 0.5 mgrml for kinase renaturation assay. The arrow
indicates the protein band at 42–44 kDa. Molecular weight
 3.markers =10 are indicated to the left of the blot. Panel B:
dose-response curve of the inhibitory effect of PD 098059 on
PAF-stimulated MBP kinase activity in the 42–44 kDa protein
band in HEC-1A cells. Quantification of the band was performed
by image analysis as described in Section 2.
Fig. 4. Effect of genistein G, 10 and 30 mM, 30 min preincuba-
.tion on PAF-stimulated c-fos gene expression in HEC-1A cells.
 .Cells were incubated with PAF 0.1 mM for 30 min. In the
upper panel hybridization of HEC-1A RNA with a cDNA probe
 .for c-fos upper blot and with rat-cyclophyllin cDNA probe
 .lower blot is shown. In the lower panel the percentage increase
of c-fos gene expression with the different treatments calculated
by densitometric analysis of the bands is reported. Representative
of at least two similar experiments.
 .using 100 mM genistein not shown . Similarly,
PAF-stimulated c-fos mRNA expression was not in-
hibited by pretreatment with the structurally unrelated
tyrosine kinase inhibitor methyl 2,5-dihydroxycin-
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 .namate 250 mM, 30 min preincubation, Fig. 5 .
Taken together these data, obtained with concentra-
tions and incubation times of methyl 2,5-dihydroxy-
cinnamate and genistein previously shown by our
w xgroup to inhibit PTK activity 16,33 seem to exclude
the involvement of tyrosine kinase in PAF-mediated
c-fos gene expression.
Fig. 5. Effect of the erbstatin analog methyl 2,5-dihydroxycin-
 .namate E, 250 mM, 30 min preincubation on PAF-stimulated
c-fos gene expression in HEC-1A cells. Cells were incubated
 .with PAF 0.1 mM for 30 min. In the upper panel hybridization
 .of HEC-1A RNA with a cDNA probe for c-fos upper blot and
 .with rat-cyclophyllin cDNA probe lower blot is shown. In the
lower panel the percentage increase of c-fos gene expression with
the different treatments calculated by ratio of densitometric anal-
ysis of the c-fos and cyclophyllin bands is reported. Representa-
tive of two similar experiments.
Fig. 6. Growth rate curve of HEC-1A cells in the presence or
 .  .absence control of PAF 1 mM . Cell number was determined
by flow cytometer as described in Section 2. Data represent mean
values of two different experiments performed in triplicate.
3.3. Effect of tyrosine kinase inhibition on PAF-
stimulated thymidine uptake
We then evaluated the effect of genistein and
w3 xmethyl 2,5-dihydroxycinnamate on H thymidine up-
take stimulated by PAF. In preliminary experiments
 .not shown we demonstrated that the effect of PAF
on thymidine uptake was already maximum at 24 h
and persisted for 48–72 h, thus 24 h stimulation was
chosen for these experiments. The growth rate curve
of HEC-1A cells withrwithout PAF confirmed that
the effect of PAF on cell growth was present at such
 .incubation time Fig. 6 . As shown in Fig. 7A, 30 and
100 mM concentrations of genistein inhibited PAF 3
. w3 xmM -stimulated H thymidine uptake. Conversely,
w3 xbasal and PAF-stimulated H thymidine uptake were
unaffected by daidzein, a genistein analog found to
be 100-fold less active than genistein results not
.shown . We next investigated the effect of methyl-
2,5-dihydroxycinnamate. As shown in Fig. 7B, this
 .compound inhibited basal and PAF 3 mM -stimu-
lated DNA synthesis starting at the concentration of
10 mM. Hence, these results suggest an involvement
of PTKs in PAF-mediated DNA synthesis. We next
studied the involvement of MAPK activation in the
effect of PAF, by using PD098059. We found that
this compound slightly inhibited PAF-stimulated
thymidine uptake at the concentration of 10 mM, and
completely reversed the effect of PAF at 100 mM
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Fig. 7. Effect of increasing concentrations of genistein G, 30
.min preincubation, panel A , the erbstatin analog methyl-2,5-di-
 .hydroxycinnamate E, 30 min preincubation, panel B , and PD
 .  .098059 PD, 30 min preincubation, panel C on basal C and
 . w3 xPAF P -stimulated H thymidine uptake in HEC-1A cells.
 .Results shown are the mean"S.E.M. of 5 panel A and 3
 .panels B and C experiments, performed in triplicate.
 .Fig. 7C , suggesting an involvement of MAPK acti-
vation in the mitogenic effect of PAF in HEC-1A
cells.
3.4. Effect of PKC inhibition on PAF-induced mitoge-
nesis in HEC-1A cells
We next investigated the possible involvement of
PKC activation in PAF-induced c-fos gene expres-
sion. In order to obtain down regulation of PMA
sensitive PKC isoenzymes, cells were treated for 24 h
 .with the phorbol ester PMA 0.1 mM before addi-
 .tion of PAF 0.1 mM, 30 min incubation . As shown
in Fig. 8 upper panel, c-fos gene expression was
strongly inhibited in PKC-depleted cells either in
basal conditions or after PAF stimulation. In Fig. 8,
lower panel, the percentage increase of c-fos expres-
sion after the different treatments, obtained by den-
Fig. 8. Effect of PKC depletion after 24 h incubation with 0.1
mM of the phorbol ester PMA on PAF 0.1 mM, 30 min
.incubation -stimulated c-fos gene expression in HEC-1A cells. In
the upper panel hybridization of HEC-1A RNA with a cDNA
 .probe for c-fos upper blot and with rat-cyclophyllin cDNA
 .probe lower blot is shown. In the lower panel the percentage
increase of c-fos gene expression with the different treatments
calculated by ratio of densitometric analysis of the c-fos and
cyclphyllin bands is reported.
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Table 1
w3 xEffect of PKC inhibition on PAF-stimulated H thymidine uptake in HEC-1A cells
Control B S PMA 24h PAF PAFqB PAFqS PAFqPMA PMA 5 min PAFqPMA
24h 5 min
) ) )100"2.2 99.3"8.5 76.1"0.1 90.5"6.1 162.4"3.9 104.6"10 71.6"0.1 123.5"4.7 155.6"4.7 172"4.9
ns16 ns8 ns5 ns3 ns10 ns6 ns3 ns3 ns6 ns3
 .  .PKC was inhibited with the two different inhibitors sangivamycin S and bisindolylmaleimide B or depleted after long-term exposure
 .  .  .  .24 h to the phorbol ester PMA 0.1 mM . PKC stimulation was obtained with short-term 5 min exposure to PMA 0.1 mM . Values
represent mean"S.E.M. of percentage thymidine incorporation in the indicated number of observations.
) P-0.001 versus control.
sitometric analysis as described above, is reported.
Similar results were obtained when cells were pre-
treated with the PKC inhibitor sangivamycin results
.not shown .
The inhibitory effect of PKC inhibition on PAF-
mediated c-fos gene expression prompted us to study
the possible involvement of PKC on PAF-stimulated
thymidine uptake. As shown in Table 1, PKC inhibi-
tion with the two inhibitors sangivamycin and bisin-
w3 xdolylmaleimide blunted PAF-mediated H thymidine
incorporation. Similar results were obtained in PKC-
depleted cells after long-term stimulation with 0.1
 .mM PMA Table 1 . The involvement of PKC in
PAF-mediated thymidine uptake was further sug-
gested by the absence of an additive effect of PAF on
 .PMA 0.1 mM, 5 min stimulation -induced mitogen-
 .esis Table 1 .
4. Discussion
In the present paper we report evidence that PAF-
induced mitogenesis in HEC-1A cells is mediated by
a network of signaling pathways involving NRPTK,
MAPK and PKC activation. Our data demonstrate
 .that PAF stimulates a rapid 1–2 min phosphoryla-
tion in tyrosine residues of several cellular proteins in
HEC-1A cells. In addition, we report that tyrosine
kinase inhibition with the two structurally and me-
chanicistically unrelated PTK inhibitors genistein and
methyl-2,5-dihydroxycinnamate blunted PAF-induced
thymidine incorporation. These results suggest the
involvement of NRPTK activation in the mitogenic
effect of PAF. Recent evidence indicates that the two
PTK inhibitors used in the present study may have
additional effects beside PTK inhibition. In particu-
lar, genistein has been shown to inhibit type II topoi-
w x w xsomerases 34 , S6 kinase 35 and to revert certain
w xinsulin actions independently of PTK inhibition 36 .
Similarly, the cytotoxic effect of methyl-2,5-dihy-
droxycinnamate has been shown to be independent of
w xPTK inhibition 37 . In this light, the possibility that
non-specific effects of the two compounds might
contribute to inhibit basal and stimulated mitogenesis
in HEC-1A cells cannot be excluded. On the other
hand, both the erbstatin analog and genistein did not
prevent PAF-induced increase of c-fos gene expres-
sion whereas this effect was abolished by PKC down
regulation and pharmacological inhibition. This find-
ing, while suggesting the involvement of PKC activa-
tion in c-fos gene expression, excludes that the two
compounds have non-specific effects on PKC activity
and suggests that activation of PKC by PAF in
HEC-1A cells is independent of PTK activity.
Among the different proteins showing increased
tyrosine phosphorylation in response to PAF, two
proteins respectively in the 42 and 44 kDa molecular
weight range were immunologically identified by
immunoprecipitation studies as p42 and p44 MAPKs.
Immunokinase experiments performed either by us-
ing a monoclonal antibody directed against the p42
isoform and a polyclonal antibody that recognize
both p42 and p44 isoforms, demonstrated that the
increased tyrosine phosphorylation stimulated by PAF
in the two proteins was associated with an increase of
their activity. These results were also confirmed by
evaluation of phosphorylating activity of HEC-1A
cell proteins of MBP copolimerized with polyacryl-
 .amide ‘in-gel’ kinase assays , which revealed the
presence of several MBP phosphorylating proteins
including one at 42–44 kDa. In addition, pharmaco-
logical inhibition of MAPK cascade activation by PD
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w x098059 28–30 blunted the stimulatory effect of
PAF on MAPK activity and DNA synthesis. Taken
together, these findings strongly suggest, for the first
time, that MAPKs are involved in a biological effect
of PAF in proliferating cells. However, it must be
mentioned that in our hands, PD 098059 inhibited
PAF-stimulated MBP phosphorylation in other pro-
tein bands besides the 42–44 kDa and stimulated
MBP phosphorylation by a protein band of about
80–100 kDa. In different cells, this compound has
been shown to enhance basal activity of c-raf as well
w xas its activation by growth factors 30 , and to induce
w xa persistent activation of the ras pathway 38 . It is
possible that MAPK activation by PAF in HEC-1A
cells is involved in activation of other kinases able to
phosphorylate MBP by the phospholipid. The finding
that PD 098059 inhibits PAF-stimulated thymidine
uptake at higher concentrations than those required to
inhibit MAPK activation, further indicates that multi-
ple signaling pathways are involved in growth of
HEC-1A cells. Similarly, in cells transformed to-
wards a tumorigenic phenotype PD 098059 was found
to inhibit cell growth only at very high concentrations
w x29 .
Finally, we report evidence of the involvement of
PKC-mediated pathways in the mitogenic effect of
PAF. Indeed, we show here that PKC down regula-
tion after long-time exposure to PMA as well as its
inhibition with sangivamycin were able to revert the
stimulatory effect of PAF. Moreover, two different
PKC inhibitors and long term exposure to PMA
antagonized PAF-stimulated thymidine incorporation.
Although long-term treatment with PMA does not
down regulate all PKC isoenzymes and PKC in-
hibitors may have other effects beside PKC inhibi-
tion, taken together, our results indicate that mito-
genic signaling by PAF also requires signaling path-
ways leading to PKC activation. This hypothesis is
substantiated by the finding that short-term stimula-
tion of PKC with PMA was able to induce mitogene-
sis in these cells, and that no additive effect was
observed when cells were concomitantly stimulated
with the two agents.
In conclusion, our results suggest that multiple
signaling pathways are involved in PAF-mediated
mitogenesis in HEC-1A cells. In particular, we show
evidence that PKC activation is involved in PAF-
mediated c-fos gene expression. In addition, PAF
induces an increase of tyrosine phosphorylation of
proteins which is involved in the activation of MAPK.
The inhibitory effect of PTK, MAPK cascade and
PKC inhibition on PAF-stimulated thymidine incor-
poration suggests that these proliferative signals may
support PAF-induced mitogenesis in this cell line. As
w xpreviously reported in different cell systems 5,8 ,
cross-talks among NRPTK and PKC may also occur
further contributing in enhancing mitogenic signaling.
In a different tumor cell line, PAF stimulation of
c-fos gene expression was found to be blunted by
w xboth PKC and PTK inhibition 19 , suggesting cross-
talks between the two pathways in these cells.
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